Flerie

Flerie EBITDA per Employee

The EBITDA per Employee of Flerie (FLERIE.ST) as of Oct 16, 2026 is -130.25 M SEK. In the previous year, EBITDA per Employee was -18.33 M SEK — a change of 610.45% (lower).

EBITDA per Employee

-130.25 MSEK

YoY

610.45%

Last updated:

EBITDA per Employee of Flerie is 2025 -130.25 M SEK. EBITDA per Employee of Flerie was 2024 -18.33 M SEK. It decreases by 610.45% lower compared to the previous year.

The Flerie EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-13.61 M SEK
Jan 1, 2019
-14.46 M SEK
Jan 1, 2020
-9.42 M SEK
Jan 1, 2021
-19.06 M SEK
Jan 1, 2022
-25.01 M SEK
Jan 1, 2023
-17.69 M SEK
Jan 1, 2024
-18.33 M SEK
Jan 1, 2025
-130.25 M SEK
The Flerie EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-130.25 MSEK+610.45%
-18.33 MSEK+3.63%
-17.69 MSEK-29.26%
-25.01 MSEK+31.19%
-19.06 MSEK+102.31%
-9.42 MSEK-34.84%
-14.46 MSEK+6.25%
-13.61 MSEK+12.84%
-12.06 MSEK+82.35%
-6.62 MSEK+35.10%
-4.90 MSEK+143.30%
-2.01 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Flerie Stock analysis

What does Flerie do? Flerie AB, listed on the Stockholm Stock Exchange under the ticker FLERIE.ST, is a pharmaceutical company based in Solna, Sweden. The company has 6 employees and completed its initial public offering (IPO) on October 11, 2016. Flerie AB operates within the healthcare sector, specifically in the pharmaceuticals industry. The company's website is https://www.indexpharma.com/. Flerie AB is a parent company for InDex Pharmaceuticals AB and InDex Diagnostics AB. The company is engaged in the development of drugs for the treatment of diseases such as inflammation and cancer. It has a drug candidate named cobitolimod, which is intended for the treatment of ulcerative colitis. Additionally, Flerie AB develops a platform of patent-protected substances known as DNA-based ImmunoModulatory Sequences (DIMS), designed to treat various immunological diseases. The company also offers a diagnostic kit called DiBiCol, a PCR-based method that monitors seven biomarkers specific to ulcerative colitis or Crohn's disease from a single colonic biopsy. Shareholders of Flerie AB include SEB Venture Capital, Industrifonden, and NeoMed Management. The company's focus is on pharmaceutical development, with an emphasis on innovative treatments for inflammatory and immunological conditions. Flerie is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Flerie stock

EBITDA per Employee of Flerie is -130.25 M SEK in 2025.

EBITDA per Employee of Flerie changed from -18.33 M SEK to -130.25 M SEK, representing a 610.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Flerie since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Flerie historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Flerie

All Key Metrics — Flerie